Figure 1 | Scientific Reports

Figure 1

From: CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor

Figure 1

High expression of CSE1L correlates with worse prognosis in p53 WT NSCLC. Expression of CSE1L gene is tested for correlation with survival in all 994 NSCLC patients in TCGA. (A) High expression (≥ median) of CSE1L significantly (p = 0.009) associates with worse survival in WT p53 patients but not (p = 0.667 mutant p53 mutant patients. (B). p53 WT and p53 mutant NSCLC patients were compared for overall survival. There is no significant difference between p53 WT and p53 mutant cases. (C). CSE1L mRNA levels (FPKM) from TCGA in p53 WT tumors and p53 mutant tumors were compared. There is significant difference (p = 0.0001) between p53 WT and p53 mutant cases. (D). Patients were further stratified into four groups: CSE1L high/RBL2 low, CSE1L high/RBL2 high, CSE1L low/RBL2 low, and CSE1L low/RBL2 high. There is a significant difference between the groups in WT p53 patients (p = 0.011) but not mutant p53 patients (p = 0.565).

Back to article page